Trending

Jounce

Jounce shares crash after it abandons immunotherapy combination trial

Jounce shares crash after it abandons immunotherapy combination trial

Shares in Jounce Therapeutics are down sharply after it emerged that its immunotherapy combination with Bristol-Myers Squibb’s Yervoy

X

Jounce shares crash after it abandons immunotherapy combination trial

https://pharmaphorum.com/news/jounce-shares-crash-after-it-abandons-immunotherapy-combination-trial/

Jounce set to make first biotech IPO of 2017

Jounce set to make first biotech IPO of 2017

Massachusetts-based company will test the waters for biotech sector

X

Jounce set to make first biotech IPO of 2017

https://pharmaphorum.com/news/jounce-gets-early-lead-2017-biotech-ipos/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com